NCT01257412 - Evaluation of Efficacy and Safety of Dapagliflozin as Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycaemic Control With Diet and Exercise Alone | Biotech Hunter

Enrollment

375

Participants

Timeline

Start Date

January 31, 2012

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Type 2 Diabetes

Interventions

DRUG

Dapagliflozin

5mg Oral dose od

DRUG

Dapagliflozin

10 mg Oral dose od

DRUG

placebo

5/10 mg Oral dose od

Trial Locations (15)

Research Site, Hyderabad

Research Site, Vijaywada

Research Site, Ahmedabad

Research Site, Bangalore

Research Site, Mysore

Research Site, Trivandrum

Research Site, Indore

Research Site, Mumbai

Research Site, Nagpur

Research Site, Pune

Research Site, Jaipur

Research Site, Chennai

Research Site, Coimbatore

Research Site, Madurai

Research Site, Ghaziabad